首页> 外文期刊>Nature >CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
【24h】

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

机译:阻断CD47的抗体可恢复吞噬作用并预防动脉粥样硬化

获取原文
获取原文并翻译 | 示例
           

摘要

Atherosclerosis is the disease process that underlies heart attack and stroke(1). Advanced lesions at risk of rupture are characterized by the pathological accumulation of diseased vascular cells and apoptotic cellular debris(2). Why these cells are not cleared remains unknown(3). Here we show that atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis'(4-7). We find that administration of CD47-blocking antibodies reverses this defect in efferocytosis, normalizes the clearance of diseased vascular tissue, and ameliorates atherosclerosis in multiple mouse models. Mechanistic studies implicate the pro-atherosclerotic factor TNF-alpha as a fundamental driver of impaired programmed cell removal, explaining why this process is compromised in vascular disease. Similar to recent observations in cancer(5), impaired efferocytosis appears to play a pathogenic role in cardiovascular disease, but is not a fixed defect and may represent a novel therapeutic target.
机译:动脉粥样硬化是心脏病和中风的基础疾病(1)。处于破裂风险中的晚期病变的特征是病变血管细胞和细胞凋亡碎片的病理性堆积(2)。为什么不清除这些单元格仍然未知(3)。在这里,我们显示动脉粥样硬化与CD47的上调有关,CD47是一种关键的抗吞噬分子,已知可使恶性细胞对程序性细胞去除或“胞吞作用”产生抗性(4-7)。我们发现,施用CD47阻断抗体可逆转这种在红细胞增多症中的缺陷,使患病血管组织的清除正常化,并改善多种小鼠模型中的动脉粥样硬化。机理研究表明,动脉粥样硬化前体因子TNF-α是程序性细胞去除受损的根本驱动因素,解释了为什么这一过程在血管疾病中受损。与最近在癌症中的观察结果相似(5),血细胞增多症似乎在心血管疾病中起着致病作用,但不是固定的缺陷,可能代表了新的治疗靶点。

著录项

  • 来源
    《Nature》 |2016年第7614期|86-90|共5页
  • 作者单位

    Stanford Univ, Dept Surg, Sch Med, Div Vasc Surg, Stanford, CA 94305 USA;

    Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;

    Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;

    Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA;

    Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA;

    Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA;

    Stanford Univ, Dept Surg, Sch Med, Div Vasc Surg, Stanford, CA 94305 USA;

    Stanford Univ, Dept Surg, Sch Med, Div Vasc Surg, Stanford, CA 94305 USA;

    Stanford Univ, Dept Surg, Sch Med, Div Vasc Surg, Stanford, CA 94305 USA;

    Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA;

    Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA;

    Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA;

    Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;

    Karolinska Inst, Dept Med, Stockholm, Sweden;

    Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden;

    Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden;

    Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;

    Stanford Univ, Dept Surg, Sch Med, Div Vasc Surg, Stanford, CA 94305 USA|Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号